Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2020 | Dara, len & dex for newly-diagnosed myeloma

Shaji Kumar, MD, Mayo Clinic, Rochester, MN presents the results of the Maia study (NCT02252172), a Phase III comparison of daratumumab, lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) in patients with newly-diagnosed multiple myeloma that are ineligible for autologous stem cell transplantation. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.